Pacific Biosciences of California PACB Income Statement
| TTM Q1 '26 | TTM Q4 '25 | TTM Q3 '25 | TTM Q2 '25 | TTM Q1 '25 | ||
|---|---|---|---|---|---|---|
| $12.47M-41.5% | $14.76M-38.0% | $16.05M-42.9% | $19.95M-32.9% | $21.32M-34.6% | ||
| —— | —— | —— | —— | —— | ||
| -$128.58M+80.5% | -$546.38M-75.0% | -$506.01M-28.3% | -$528.73M-32.1% | -$660.12M-122% | ||
| $110K-97.8% | $4.18M+319% | $4.17M-6.0% | $4.09M-7.7% | $5.07M+47.4% | ||
| $3.33M-99.1% | $364.54M+1,925% | $368.34M+1,860% | $371.15M+2,236% | $374.54M+3,111% | ||
| —— | —— | —— | —— | —— | ||
| $4.08M-98.9% | $369.45M+1,248% | $375.28M+1,598% | $381.12M+2,171% | $386.95M+3,273% | ||
| $0+100% | -$18.7M-2,100% | -$20.65M-1,039% | -$19.48M-2,667% | -$19.48M-813% | ||
| $10.06M-35.8% | $12.99M-5.7% | $13.09M-5.9% | $14.83M+17.5% | $15.67M+31.1% | ||
| —— | —— | —— | —— | —— | ||
| —— | $0-100% | $38.6M-66.7% | $77.2M0.0% | $115.81M+200% | ||
| $0— | $15M— | —— | —— | —— | ||
| -$315K— | $2.48M— | $4.39M— | -$2.49M— | —— | ||
| —— | —— | —— | -$176K— | —— | ||
| $3.16M— | $3.16M— | —— | —— | —— | ||
| —— | —— | —— | —— | —— | ||
| -$2.8M— | -$8.51M— | —— | —— | —— | ||
| —— | $8.26M-44.2% | $9.9M-34.1% | $11.53M-24.3% | $13.17M-14.8% | ||
| —— | —— | —— | —— | -$47.58M— | ||
| $106.07M-47.8% | $115.45M-6.9% | $147.66M— | $151.82M— | $203.37M— | ||
| -$111.84M+35.9% | -$111.21M+46.0% | -$122.79M+47.3% | -$149.55M+40.8% | -$174.43M+27.4% | ||
| —— | —— | —— | —— | $5M— | ||
| $207.54M-43.7% | $216.91M-56.5% | $264.29M-57.4% | $313.06M-46.3% | $368.55M-48.5% | ||
| $4.45M— | $2.8M— | $3.56M— | —— | —— | ||
| $274.88M-49.6% | $340.07M-42.7% | $393.62M-36.4% | $437.8M-46.0% | $545.76M-28.9% | ||
| $36.93M-39.2% | $41.67M-41.3% | $48.11M-32.8% | $55.39M-24.1% | $60.71M-17.6% | ||
| -$119.15M+71.6% | -$171.43M+60.4% | -$277.32M+24.5% | -$294.95M+25.0% | -$419.27M-40.8% | ||
| -$133.28M+83.8% | -$553.86M-16.8% | -$665.69M-62.8% | -$690.89M-61.7% | -$821.89M-153% |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- What is Pacific Biosciences of California's revenue?
- Pacific Biosciences of California (PACB) generated $160.0M in revenue over the trailing twelve months, up 5.0% year over year.
- Is Pacific Biosciences of California profitable?
- Pacific Biosciences of California is not currently profitable: it reported a net loss of $128.6M over the trailing twelve months, a -80.3% net margin.
- What are Pacific Biosciences of California's profit margins?
- Gross margin is 37.5% and operating margin is -83.3%, with a -80.3% net margin.
- What is Pacific Biosciences of California's earnings per share?
- Pacific Biosciences of California's diluted EPS over the trailing twelve months is $-0.43.
- Where does Pacific Biosciences of California's income statement data come from?
- Every line is extracted from Pacific Biosciences of California's SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.
